Is AbbVie Stock Too Cheap to Ignore at Today's Price?

AbbVie is presented as an attractively valued pharma pick: it trades at about 16.8x forward earnings (below the healthcare sector average of 18.3 and the S&P 500 at 22.6) with a PEG ratio around 0.43, suggesting potential undervaluation. The company’s near-term growth is expected to be driven by immunology staples Skyrizi and Rinvoq—approved across multiple indications and not facing imminent patent expiry—while management points to a large pipeline and no major patent cliff through the late 2020s as additional upside. Combined with a 54-year dividend-growth streak, the article frames AbbVie as a compelling income and total-return candidate, though the author notes Motley Fool’s Stock Advisor did not include AbbVie in its current top-10 buy list.

Analysis

AbbVie trades at about 16.8x forward earnings versus the healthcare-sector average of 18.3x and the S&P 500 at 22.6x, and carries a PEG ratio near 0.43, metrics the article cites as evidence the stock is undervalued. The company has absorbed patent cliff pressures and clinical setbacks over the past three years that weighed on the share price, yet the piece notes the stock still performed resiliently despite those headwinds.

The firm's near-term growth thesis rests on immunology franchises Skyrizi and Rinvoq, which are approved across multiple indications (plaque psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis) and are not facing imminent patent expiries; the article states AbbVie faces no major patent cliff through the late 2020s and has a pipeline of several dozen assets where even a few approvals or label expansions could be material. This structural revenue visibility underpins the valuation argument and expected revenue/earnings growth through at least 2030.

AbbVie is highlighted as a strong income name, inheriting a Dividend King streak now at 54 years, supporting total-return cases for yield-focused investors. The signal set attached to the article is moderately positive (sentiment score 0.55) with limited market-impact (0.3), but investors should remain attentive to regulatory/clinical readouts and execution risk given prior setbacks and the author’s note that AbbVie was not in the Stock Advisor top-10 list.

Key Decisions for Investors

• Income-oriented investors should consider initiating or modestly adding to AbbVie positions given the 54-year dividend streak and apparent valuation gap relative to sector and market averages
• Increase weight only if forthcoming quarterly results and commercial trends confirm continued momentum for Skyrizi and Rinvoq or if visible approvals/label expansions materialize,
• Monitor near-term catalysts closely — clinical readouts, regulatory approvals, patent-expiry timelines and product sales trends — and be prepared to trim on missed execution or negative trial news,
• Manage position size or hedge downside exposure because prior clinical setbacks and patent-related risks, while reduced through the late 2020s, still present execution risk that could widen volatility